Skip to main content

Kling Douglas F's Form 4 filing

NewAmsterdam Pharma Co N.V. (NAMS) · filed Jan 31, 2025

Accession no.
0000950170-25-011854
Filed
Jan 31, 2025
Trade date
Jan 29-30, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kling Douglas FCIK 0001699022Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 29, 2025Ordinary SharesMOption exerciseAcquired+56,863––100,863Direct
Jan 29, 2025Ordinary SharesSSaleDisposed−56,863––44,000Direct
Jan 30, 2025Ordinary SharesMOption exerciseAcquired+13,578––57,578Direct
Jan 30, 2025Ordinary SharesSSaleDisposed−4,664––52,914Direct
Jan 30, 2025Ordinary SharesSSaleDisposed−8,914––44,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 29, 2025Ordinary SharesMOption exerciseDisposed−56,863$0.00$0239,723Direct
Jan 30, 2025Ordinary SharesMOption exerciseDisposed−13,578$0.00$0226,145Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)